Methodological review reveals computational frameworks combining chemoinformatics and molecular dynamics for target selectivity, suggesting enhanced precision in small-molecule drug design.
This presentation will describe how structural biology, molecular pharmacology, and medicinal chemistry studies can be combined with molecular modeling and chemoinformatics analyses for a more accurate description and prediction of structural determinants of protein-ligand binding, functional activity, and selectivity. The challenges and possibilities of structural chemogenomics studies will be discussed, including the integration of large volumes of heterogeneous pharmacological and chemical data for different protein targets and the development of structure-based virtual screening and computer-aided drug design approaches to discover novel small molecule ligands with well defined functional activity and protein selectivity profiles. The potential of molecular dynamics simulation methods to complement hybrid structural biology studies will be demonstrated for the investigation the mechanisms of conformational selection and protein-ligand binding kinetics. In the final part of the presentation structural protein-ligand interaction databases will be described that link structure-based protein-ligand interaction maps to protein ligand topology and can be used as structural chemogenomics tools to navigate medicinal chemistry space.
No takes yet. Share an insight, caveat, or question.
Fechner et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: